title: Dendritic-cell-based technology landscape: Insights from patents and citation networks.
abstract: As the most potent antigen-presenting cells, dendritic cells (DCs) are pivotal players in regulating immune responses. DC-based technologies have generated a series of typical and promising therapeutic options, especially after the first DC-based cancer vaccine was approved by US. Food and Drug Administration (US. FDA). In this context, this paper employs patents and citation networks to conduct a fundamental analysis in order to show overall landscape of DC-based technologies. The results in this research can be used as references for decision-making in developing efficacious DC therapeutic products.
authors.affiliation: a State Key Laboratory of Quality Research in Chinese Medicine ; Institute of Chinese Medical Sciences; University of Macau ; Macau SAR , China.
authors.forename: Xiangjun
authors.initials: X
authors.lastname: Kong
authors.forename: Yuanjia
authors.initials: Y
authors.lastname: Hu
authors.forename: Zhifang
authors.initials: Z
authors.lastname: Cai
authors.forename: Fengqing
authors.initials: F
authors.lastname: Yang
authors.forename: Qianru
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D003713:Dendritic Cells / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D010330:Patents as Topic
keywords: DC, dendritic cell; R&D, research and development; US. FDA, US. Food and Drug Administration; US. PTO, US. Patent and Trademark Office; USPC, US. Patent Classification; citation network; dendritic cells; immunotherapy; patent landscape; patent ownership; patenting strategy; technology development